logoTry Persana

Nektar Therapeutics - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Nektar Therapeutics including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Nektar Therapeutics company logo

Developing innovative medicines in biotechnology.

Nektar Therapeutics is a research-based biopharmaceutical company focusing on innovative medicines to meet significant medical needs in oncology and immunology.

HeadquartersSan Francisco, United States
Team size500
Founded1990

What is Nektar Therapeutics? - Company Overview & Details

Nektar Therapeutics is Nektar Therapeutics is a research-based biopharmaceutical company focusing on innovative medicines to meet significant medical needs in oncology and immunology. Founded in 1990, the company is headquartered in San Francisco, United States.

Who are the Key Executives at Nektar Therapeutics? - Leadership Team

Nektar Therapeutics is led by experienced executives in key positions:

Nektar Therapeutics Company Details & Key Information

Where is Nektar Therapeutics located?

Nektar Therapeutics is headquartered in San Francisco, United States.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics has 500 employees.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

How much funding has Nektar Therapeutics raised?

Nektar Therapeutics has raised $150 million across 8 funding rounds. The most recent funding was completed on 2025-08-01.

Funding Overview

Nektar Therapeutics has raised significant funds in its quest to develop therapies for complex medical conditions.

$150 million
Total Funding Raised
8
Funding Rounds
2025-08-01
Latest Round

Nektar Therapeutics Funding History

Post IPO equity
2025-08-01
$150 million

Who are the key investors in Nektar Therapeutics?

Nektar Therapeutics is backed by 1 key investors including SFJ Pharmaceuticals. These investors focus on Biotechnology, Pharmaceutical Development sectors.

Nektar Therapeutics Investor Overview

1
Key Investors
2
Focus Areas
1
Notable Investments

Complete List of Nektar Therapeutics Investors

SFJ Pharmaceuticals

A major investor focused on biopharmaceuticals.

Investment Focus
Biotechnology
Pharmaceutical Development
Notable Portfolio Companies
Nektar Therapeutics

What sectors do Nektar Therapeutics investors focus on?

The investors backing Nektar Therapeutics primarily focus on Biotechnology, Pharmaceutical Development sectors.

Biotechnology
Pharmaceutical Development

Featured Investor: SFJ Pharmaceuticals

SFJ Pharmaceuticals

A major investor focused on biopharmaceuticals.

Notable Investments: Nektar Therapeutics

What are Nektar Therapeutics's future plans?

Nektar Therapeutics Nektar plans to further advance its pipeline and expand partnerships for clinical studies.

Nektar Therapeutics Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Nektar Therapeutics face?

Nektar Therapeutics has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Nektar Therapeutics

1

Regulatory hurdles

2

Market competition

What opportunities does Nektar Therapeutics have?

Nektar Therapeutics has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Nektar Therapeutics

1

Expanding therapeutic indications

2

Innovative drug development partnerships

Nektar Therapeutics Strategic Position Summary

Key Focus Areas

Nektar Therapeutics is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Nektar Therapeutics?

Nektar Therapeutics has 2 recent news updates covering key business developments and market activities.

Nektar Therapeutics News Overview

2
Recent Articles
Active
Media Coverage
2025-07-02
Latest Update

What is Nektar Therapeutics in the news for?

Nektar Therapeutics is currently featured in news for Nektar Therapeutics receives financing of $115M in public offering. and other significant business developments.

Recent News Articles About Nektar Therapeutics

Article 1
2025-07-02

Nektar Therapeutics receives financing of $115M in public offering.

Nektar Therapeutics announces closing of $115 million public offering.

nektar.com
Read News
Article 2
2025-07-17

Nektar Therapeutics launches LX mk3.

Nektar introduces impact LX mk3, the latest generation of MIDI keyboards designed to enhance creativity.

rock-distribution.com
Read News

Nektar Therapeutics FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Nektar Therapeutics including information about founders, CEO, funding history, investors, headquarters location, and company details. 14 frequently asked questions covering key information about the company.

Nektar Therapeutics Questions & Answers - Company Information

Q1

What is Nektar Therapeutics?

Nektar Therapeutics is a research-based biopharmaceutical company focusing on innovative medicines to meet significant medical needs in oncology and immunology.

Q2

How much funding has Nektar Therapeutics raised?

Nektar Therapeutics has raised a total of $$150 million across 8 funding rounds. The most recent funding was completed on 2025-08-01.

Q3

Who are the investors in Nektar Therapeutics?

Nektar Therapeutics's key investors include SFJ Pharmaceuticals.

Q4

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in San Francisco, United States.

Q5

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

Q6

How many employees does Nektar Therapeutics have?

Nektar Therapeutics has 500 employees.

Q7

What was Nektar Therapeutics's latest funding round?

Nektar Therapeutics's latest funding round was a Post IPO equity round of $$150 million completed on 2025-08-01.

Q8

What does the company do?

Nektar Therapeutics develops innovative medicines to meet significant medical needs in oncology and immunology.

Q9

How much funding?

$150 million

Q10

Latest funding date?

2025-08-01

Q11

Who are the investors?

SFJ Pharmaceuticals

Q12

What are the challenges?

Regulatory hurdles Market competition

Q13

What are the opportunities?

Expanding therapeutic indications Innovative drug development partnerships

Q14

Latest news?

Nektar Therapeutics announces closing of $115 million public offering. Nektar introduces impact LX mk3, the latest generation of MIDI keyboards designed to enhance creativity.

More Information About Nektar Therapeutics

For additional details about Nektar Therapeutics, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.